(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 May 2015 (21.05.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/073895 A1

(51) International Patent Classification:
A61K 31/573 (2006.01) *A61K 9/00* (2006.01)
A61K 9/10 (2006.01) *A61P 27/02* (2006.01)

(21) International Application Number:
PCT/US2014/065804

(22) International Filing Date:
14 November 2014 (14.11.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/904,887 15 November 2013 (15.11.2013) US

(71) Applicant: **ALLERGAN, INC.** [US/US]; 2525 Dupont Drive, Irvine, California 92612 (US).

(72) Inventors: **SHIAH, Jane-Guo**; 16 Lucero West, Irvine, California 92620 (US). **BHAGAT, Rahul**; 47 Fillmore, Irvine, California 92620 (US). **BLANDA, Wendy M.**; 158 N. B Street, Tustin, California 92780 (US). **NIVAGGIOLI, Thierry**; 99 Lupin Lane, Atherton, California 94027 (US). **PENG, Lin**; Suite 505, 400 Oyster Point Blvd., South San Francisco, California 94080 (US). **CHOU, David**; 2918 Kipling Street, Palo Alto, California 94306 (US). **WEBER, David A.**; Suite 100, 5626 Oberlin Drive, San Diego, California 92121 (US).

(74) Agents: **WINE, Laura L.** et al.; 2525 Dupont Drive, Irvine, California 92612 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

WO 2015/073895 A1

(54) Title: METHODS OF TREATMENT OF OCULAR CONDITIONS WITH A SUSTAINED DRUG DELIVERY IMPLANT

	DEX 700, n (%) (N = 347)	DEX 350, n (%) (N = 343)	Sham, n (%) (N = 350)
Trabeculectomy	1 (0.3%)	1 (0.3%)	0 (0.0%)
Iridectomy	1 (0.3%)	0 (0.0%)	1 (0.3%)
Iridotomy	1 (0.3%)	1 (0.3%)	0 (0.0%)
Trabeculoplasty	1 (0.3%)	1 (0.3%)	0 (0.0%)

FIG. 7

(57) Abstract: Intraocular implants may include a corticosteroid and a biodegradable polymer associated with the corticosteroid to facilitate the release of the corticosteroid into an eye for a period of time. In some embodiments, ocular conditions, such as diabetic macular edema can be treated through administration of an intraocular implant including a corticosteroid and a biodegradable polymer associated with the corticosteroid to the eye of a human at a frequency of about once every six months to about once a year.